Randy Scott will lead a new subsidiary at Genomic Health that will focus on integrating genomic data into clinical practice for patients with common and rare genetic conditions. Scott will step down as Genomic Health's executive chairman but will remain a board member, while CEO Kim Popovits will assume the role of chairman.

Scott is a founder of Genomic Health and was previously CEO of the company. He also founded Incyte, where he served in various positions including chief scientific officer; and has served as senior director of research at Invitron.

Genomic Health has also appointed Julian Baker to be lead independent director. Baker has served on the firm's board since 2001 and is a managing partner at Baker Brothers Investments. He is also a director of Incyte, Neurogen, Theravance, and Trimeris.

Life Technologies this week named Alan Sachs as head of global research and development and Ronnie Andrews as president of medical sciences.

Sachs was previously the vice president of exploratory and translational sciences for Merck Research Laboratories, where he spent 10 years in various leadership roles, Life Tech said. Prior to that Sachs served an associate professor of biochemistry and molecular biology at the University of California, Berkeley, and as a Whitehead fellow at the Whitehead Institute for Biomedical Research.

Andrews joins Life Tech from GE Molecular Diagnostics, where he served as a segment leader following GE's 2010 acquisition of Clarient, where Andrews was CEO. Andrews has also held executive positions with Abbott Diagnostics, Roche Diagnostics, and Immucor.